107 related articles for article (PubMed ID: 9554487)
1. Multicenter evaluation of the Bayer Immuno I CA 15-3 assay.
Cheli CD; Morris DL; Kish L; Goldblatt J; Neaman I; Allard WJ; Yeung KK; Wu AH; Moore R; Chan DW; Fritsche HA; Schwartz MK; Very DL
Clin Chem; 1998 Apr; 44(4):765-72. PubMed ID: 9554487
[TBL] [Abstract][Full Text] [Related]
2. Quantification of MUC1 in breast cancer patients. A method comparison study.
Bon GG; van Kamp GJ; Verstraeten RA; von Mensdorff-Pouilly S; Hilgers J; Kenemans P
Eur J Obstet Gynecol Reprod Biol; 1999 Mar; 83(1):67-75. PubMed ID: 10221613
[TBL] [Abstract][Full Text] [Related]
3. Analytical evaluation of the testosterone assay on the Bayer Immuno 1 system.
Lévesque A; Letellier M; Swirski C; Lee C; Grant A
Clin Biochem; 1998 Feb; 31(1):23-8. PubMed ID: 9559220
[TBL] [Abstract][Full Text] [Related]
4. A multicentre evaluation of the CA 15-3 assay, CA 19-9 assay and CA 125 II assay on the Bayer Immuno 1 System.
Römer M; Haeckel R; Brux B; Sinha P; Raiko I; Krieg M; Stark M; Seidel D; Hübner U; Schmitz G
Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):637-44. PubMed ID: 9298356
[TBL] [Abstract][Full Text] [Related]
5. Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays.
Bon GG; von Mensdorff-Pouilly S; Kenemans P; van Kamp GJ; Verstraeten RA; Hilgers J; Meijer S; Vermorken JB
Clin Chem; 1997 Apr; 43(4):585-93. PubMed ID: 9105258
[TBL] [Abstract][Full Text] [Related]
6. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System.
Molina R; Gion M; Gressner A; Troalen F; Auge JM; Holdenrieder S; Zancan M; Wycislo M; Stieber P
Clin Chem Lab Med; 2008; 46(5):612-22. PubMed ID: 18598203
[TBL] [Abstract][Full Text] [Related]
7. Multicenter evaluation of the performance and clinical utility in longitudinal monitoring of the Bayer Immuno 1 complexed PSA assay.
Allard WJ; Cheli CD; Morris DL; Goldblatt J; Pierre Y; Kish L; Chen Y; Dai J; Vessella RL; Chan DW; Schwartz MK; Zhou Z; Yeung KK
Int J Biol Markers; 1999; 14(2):73-83. PubMed ID: 10399626
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation comparing AxSYM CA 15-3, IMx CA 15-3 and Truquant BRTM RIA.
Lynch DM; Rogers PE; Love JC; Salkas MJ; Skarphol KA; Gross ME; Lu MG; Petrides VH; Bruzek DJ; Cox JL; Jones KA; Kelley CA; Chan DW
Tumour Biol; 1998; 19(6):421-38. PubMed ID: 9817970
[TBL] [Abstract][Full Text] [Related]
9. Multicenter evaluation of the Abbott IMx CA 15-3 assay.
van Kamp GJ; Bon GG; Verstraeten RA; Lynch D; Krikau M; Flückiger J; Ruibal A; Kenemans P
Clin Chem; 1996 Jan; 42(1):28-33. PubMed ID: 8565228
[TBL] [Abstract][Full Text] [Related]
10. Automated assay for HER-2/neu in serum.
Payne RC; Allard JW; Anderson-Mauser L; Humphreys JD; Tenney DY; Morris DL
Clin Chem; 2000 Feb; 46(2):175-82. PubMed ID: 10657373
[TBL] [Abstract][Full Text] [Related]
11. BR-MA, OM-MA, GI-MA and CEA: clinical evaluation using the IMMULITE analyzer.
van Dalen A
Tumour Biol; 1999; 20(3):117-29. PubMed ID: 10213919
[TBL] [Abstract][Full Text] [Related]
12. Analytical and clinical evaluation of an electrochemiluminescence immunoassay for the determination of CA 125.
van Ingen HE; Chan DW; Hubl W; Miyachi H; Molina R; Pitzel L; Ruibal A; Rymer JC; Domke I
Clin Chem; 1998 Dec; 44(12):2530-6. PubMed ID: 9836722
[TBL] [Abstract][Full Text] [Related]
13. Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125-detecting assays.
Davelaar EM; Schutter EM; von Mensdorff-Pouilly S; van Kamp GJ; Verstraeten RA; Kenemans P
Ann Clin Biochem; 2003 Nov; 40(Pt 6):663-73. PubMed ID: 14629806
[TBL] [Abstract][Full Text] [Related]
14. Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum.
Morris DL; Dillon PW; Very DL; Ng P; Kish L; Goldblatt JL; Bruzek DJ; Chan DW; Ahmed MS; Witek D; Fritsche HA; Smith C; Schwartz D; Schwartz MK; Noteboom JL; Vessella RL; Yeung KK; Allard WJ
J Clin Lab Anal; 1998; 12(1):65-74. PubMed ID: 9484672
[TBL] [Abstract][Full Text] [Related]
15. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.
Chan DW; Beveridge RA; Muss H; Fritsche HA; Hortobagyi G; Theriault R; Kiang D; Kennedy BJ; Evelegh M
J Clin Oncol; 1997 Jun; 15(6):2322-8. PubMed ID: 9196146
[TBL] [Abstract][Full Text] [Related]
16. New immunoassays for MUC1 in breast cancer.
Norum LF; Sauren AM; Rye PD; Nustad K
Tumour Biol; 2001; 22(4):216-22. PubMed ID: 11399946
[TBL] [Abstract][Full Text] [Related]
17. Analytical and clinical evaluation of a procedure for measuring CA 15-3 in the IMx analyser.
Ortega MD; Maestro ML; Encabo G; Varón C; Allende MT; Martinez I; Palacios G
Tumour Biol; 1996; 17(2):110-6. PubMed ID: 8658013
[TBL] [Abstract][Full Text] [Related]
18. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma.
Alber B; Hein R; Garbe C; Caroli U; Luppa PB
Clin Chem Lab Med; 2005; 43(5):557-63. PubMed ID: 15899680
[TBL] [Abstract][Full Text] [Related]
19. New markers for breast carcinoma-associated antigen in comparison with CA 15-3.
van Dalen A
Anticancer Res; 1996; 16(4B):2339-43. PubMed ID: 8694566
[TBL] [Abstract][Full Text] [Related]
20. Performance characteristics of seven automated CA 15-3 assays.
Slev PR; Rawlins ML; Roberts WL
Am J Clin Pathol; 2006 May; 125(5):752-7. PubMed ID: 16707378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
